Differences

This shows you the differences between two versions of the page.

@@ Line 1: / Line 1: @@
+~~NOTOC~~
+====== Applications to the FDA for orphan drug status for Marshall Protocol medications ======
+Autoimmunity Research Foundation has submitted multiple applications to the Office of Orphan Products Development, a division of the FDA. The goal of submitting these applications would be to make it easier for doctors to prescribe and harder for insurance companies to deny coverage of MP medications.
+===== Minocycline =====
+  * submitted by ARF (September 2005) - [[https://autoimmunityresearch.org/orphan-app-mino.pdf|Application for Orphan Drug Status]] for minocycline in sarcoidosis
+  * FDA approval (March 2006) - [[https://www.fda.gov/orphan/designat/alldes.rtf|minocycline]] as an orphan drug for sarcoidosis
+===== Clindamycin =====
+  * submitted by ARF (September 2005) - [[https://autoimmunityresearch.org/orphan-clindamycin-25jul06.pdf|Application for Orphan Drug Status]] for clindamycin in treatment of sarcoidosis and Post-Treatment Lyme Disease Syndrome
+  * FDA approval (August 2006) - [[https://www.fda.gov/orphan/designat/alldes.rtf|clindamycin]] as an orphan drug for sarcoidosis
+<html>
+<!--
+===== Olmesartan =====
+  * submitted by ARF (July 2006) - [[https://autoimmunityresearch.org/orphan-app-benicar.pdf|Application for Orphan Drug Status]] for olmesartan in treatment of Post-Treatment Lyme Disease Syndrome
+  * //application pending//
+--!</html>
+{{tag>applications FDA orphan_drugs}}